Contact lens sales have been a major contributor to Johnson & Johnson’s strong worldwide sales growth, along with new product launches and a growing pharmaceuticals business.
The company reported worldwide sales growth of US$17.8 billion in the third quarter 2016, an increase of 4.2 per cent on the same period in 2015. U.S. sales rose at an even stronger pace of 6.7 per cent.
J&J also reported net income of $4.27 billion for the recent quarter. This compared with $3.36 billion in the year-ago quarter.
In its vision care group, J&J reported worldwide sales increased 8.2 per cent to $739 million in the third quarter, and on an operational basis (excluding the impact of currency fluctuations) the increase was 5.5 per cent for the quarter. The company noted that within the US market, vision care volume growth was “partially offset by prior period inventory build for [Acuvue] Oasys 1-Day” contact lenses. J&J also noted that strong results by Acuvue contact lenses helped drive the performance in vision care business.
